US FDA declines to approve Fortress Bio and Zydus' treatment for a rare pediatric disease ReutersOctober 1, 2025 at 7:33 AM 0 FILE PHOTO: A U.S. Food and Drug Administration (FDA) logo, a syringe and a vial are seen in this illustration taken May 13, 2025.
- - US FDA declines to approve Fortress Bio and Zydus' treatment for a rare pediatric disease
ReutersOctober 1, 2025 at 7:33 AM
0
FILE PHOTO: A U.S. Food and Drug Administration (FDA) logo, a syringe and a vial are seen in this illustration taken May 13, 2025. REUTERS/Dado Ruvic/Illustration/File Photo
(Reuters) -Fortress Biotech on Wednesday said the U.S. Food and Drug Administration declined to approve the drug it is developing with Indian drugmaker Zydus Lifesciences for treating a type of rare genetic disease in children.
The FDA in its "complete response letter" pointed to deficiencies at the facility where the drug, CUTX-101, is manufactured, the company said, adding that the regulator did not cite issues with efficacy and safety data.
The drug was being developed to treat Menkes disease, where patients are born without the ability to absorb copper from their diet. It is caused by mutations in a particular gene that is responsible for the transportation of copper throughout the body.
(Reporting by Padmanabhan Ananthan and Sneha S K in Bengaluru; Editing by Vijay Kishore)
Source: "AOL AOL General News"
Source: GL MAG
Full Article on Source: GL MAG
#LALifestyle #USCelebrities